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OBJECTIVES The study aimed to evaluate the role of obesity in the prognosis of patients with heart failure
(HF).
BACKGROUND Previous reports link obesity to the development of HF. However, the impact of obesity in
patients with established HF has not been studied.
METHODS We analyzed 1,203 patients with advanced HF followed in a comprehensive HF management
program. The patients were subclassified into categories of body mass index (BMI) defined
as: underweight BMI ,20.7 (n 5 164), recommended BMI 20.7 to 27.7 (n 5 692),
overweight BMI 27.8 to 31 (n 5 168) and obese BMI .31 (n 5 179). This sample size
allows the detection of small effects (0.02), with a power of 0.80 and an alpha level of 0.05
for comparing one-year survival between BMI groups.
RESULTS The four BMI groups had similar profiles in terms of ejection fraction (mean 0.22), sodium,
creatinine and smoking. The obese and overweight groups had significantly higher rates of
hypertension and diabetes, as well as higher levels of cholesterol, triglycerides and low density
lipoprotein cholesterol. The four BMI groups had similar survival rates. Ejection fraction, HF
etiology and angiotensin-converting enzyme inhibitor use predicted survival on univariate
analysis (p , 0.01), although BMI did not. On multivariate analysis, cardiopulmonary
exercise tests, pulmonary capillary wedge pressure and serum sodium were strong predictors
of survival (p , 0.05). Higher BMI was not a risk factor for increased mortality, but was
associated with a trend toward improved survival.
CONCLUSIONS In a large cohort of patients with advanced HF of multiple etiologies, obesity is not associated
with increased mortality and may confer a more favorable prognosis. Further studies need to
delineate whether weight loss promotion in medically optimized patients with HF is a
worthwhile therapeutic goal. (J Am Coll Cardiol 2001;38:789–95) © 2001 by the American
College of Cardiology
Heart failure (HF) is an increasingly important cause of
morbidity and mortality. The annual incidence of HF in the
U.S. has recently been estimated at 465,000 and is steadily
rising, despite advances in medical therapy. Five-year sur-
vival rates are near 50% (1). Obesity is regarded as a
significant risk factor for cardiovascular disease and has also
been linked to the development of HF (2,3). A body mass
index (BMI) ,25 is generally considered healthy, yet over
half of U.S. adults have a BMI .25 and over one-third have
a BMI .27 (4,5). Elevated BMI and obesity have been
associated with the cardiovascular disease risk factors of
hypertension, insulin resistance and dyslipidemia (6). Fur-
thermore, deleterious hemodynamic and morphologic car-
diovascular changes have been attributed to obesity, even in
the absence of clinical cardiac disease. Obesity-associated
alterations include left ventricular (LV) hypertrophy, dia-
stolic dysfunction, increased LV end-diastolic dimension
(LVEDD), increased circulating blood volume, increased
cardiac output and a decreased stroke work to LV end-
diastolic pressure index (7,8). There have been reports of
HF occurring in morbidly obese individuals, with reversal of
HF on weight loss, and several investigators have suggested
the concept of an obesity-related cardiomyopathy (9–11).
In light of evidence that obesity is harmful to cardiovas-
cular health, weight loss is often recommended as a thera-
peutic goal to patients with HF and excess body fat (12).
However, no published study has addressed the question of
obesity’s impact on survival in patients with established HF.
As pharmacologic weight loss measures with potentially
adverse effects become increasingly available and more
widely utilized, obesity’s role in the prognosis of patients
with HF needs to be clarified. To investigate this issue, we
examined the relationship between obesity and mortality in
a large cohort of patients with advanced HF of multiple
etiologies.
METHODS
Study subjects. A total of 1,734 patients were referred to a
university medical center for heart transplant evaluation
between 1983 and 1999. All subjects were followed in a
comprehensive HF management program, as previously
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described (13). Medical record review was approved by the
Medical Institutional Review Board. Patients with LV
ejection fraction (LVEF) .40% (n 5 106) and those
without adequate height, weight and initial follow-up data
(n 5 425) were excluded from the analysis. The final study
group consisted of 1,203 subjects (76.6% male, age range 16
to 82 years). New York Heart Association functional class
was class II in 5.5% of patients, class III in 33.3% and class
IV in 60.6%. Mean LVEF was 22%. Etiologies of HF were
ischemic (48%), idiopathic (40%) and valvular (4.5%); the
remaining 7.5% had alcohol-induced, hypertrophic and
postpartum cardiomyopathy.
Baseline data. Body mass index—weight in kilograms
divided by square height in meters—strongly correlates with
total fat mass and was used as the primary index of obesity
in our study (2). Percent ideal body weight (PIBW) was
used as an alternate index of total body fat. For PIBW
calculations, ideal body weight was considered 48.2 kg for
men 152.4-cm (5 feet) tall and 45.5 kg for women 152.4-cm
tall, with 2.3 kg added for each additional 2.5 cm of height
(14). Height data were recorded at the time of initial referral
or at subsequent clinic visits. To eliminate edematous
weight as a confounder of accurate body weight measure-
ments, BMI and PIBW calculations were made using the
patients’ weights recorded at the time of hospital discharge,
at conclusion of pulmonary artery (PA) catheter-guided
therapy to achieve optimal hemodynamic variables and
euvolemia. The hemodynamic variables employed in the
analyses were likewise the optimal values recorded after PA
catheter-tailored medical therapy, as these hemodynamic
measurements have been shown to correlate best with
survival (15). The medical treatments recorded were those
implemented after baseline hemodynamic evaluation. Lab-
oratory testing, echocardiography and cardiopulmonary ex-
ercise tests all occurred within three months of the initial
referral; later values were excluded from our analysis. A
history of hypertension, diabetes and hypercholesterolemia
was determined from a review of medical records.
End points. Death was the primary end point in this study.
Deaths were classified as sudden death, HF death or death
secondary to myocardial infarction. Death was considered
sudden if it occurred out of the hospital within 15 min of
the onset of unexpected symptoms or during sleep. Death
during the hospital period for worsening congestive symp-
toms was considered as HF death. Urgent heart transplants
(status I) were analyzed as HF deaths, under the assumption
that these patients would have died without a transplant.
Nonurgent transplants (status II) were considered as non-
fatal at the end of follow-up.
Statistical analysis. Patients were classified into four BMI
categories, based on the National Center of Health Statis-
tics categories: underweight (BMI ,20.7), recommended
weight (BMI 20.7 to 27.7), overweight (BMI 27.8 to 31)
and obese (BMI .31) (4). The PIBW was divided into five
categories: ,80%, 80% to 100%, 101% to 120%, 121% to
140% and .140%. We calculated proportions and mean
values of baseline characteristics for the four BMI groups
and five PIBW groups. Actuarial survival curves for the four
BMI groups and five PIBW groups were calculated using
the Kaplan-Meier estimate, and differences between curves
were calculated using the log-rank statistic. Univariate
survival analyses were performed with the likelihood ratio
test, using the Cox model for baseline variables of BMI,
PIBW, age, gender, etiology, medicine use, echocardio-
graphic, exercise testing and electrocardiographic results,
initial blood tests and hemodynamic variables, Multivariate
analysis was performed by Cox proportional hazards regres-
sion analysis, using the SPSS version 10.0.5 statistical
package, to estimate adjusted odds ratios and 95% confi-
dence intervals for potential predictors of survival. The Cox
model included variables found to be significant predictors
of survival on univariate analysis and retained all indepen-
dent variables with a p value ,0.10. Power analysis for a
logistic regression model with 15 covariates indicated that a
sample of 1,200 subjects would allow the detection of small
effects (0.02), with a power of 0.80 for comparing one-year
survival between BMI groups, at an alpha level of 0.05. For
five-year survival, this same sample size would allow the
detection of moderate effects (0.15) between the BMI
groups, with a power of 0.80 and an alpha level of 0.05.
RESULTS
Almost one-third of the patients were above the recom-
mended BMI range, with the overweight and obese groups
comprising 14.0% and 14.9% of the cohort, respectively.
Fifty-nine patients had a BMI .35 and 15 patients had a
BMI .40. The majority of patients (57.5%) were in the
recommended BMI category, and 164 patients (13.6%) fell
below the recommended weight. When patients were strat-
ified by PIBW categories (,80%, 80% to 100%, 101% to
120%, 121% to 140% and .140%), the groups comprised
2.1%, 21.8%, 35.7%, 24.9% and 15.5% of the total cohort,
respectively.
Tables 1, 2 and 3 show the baseline characteristics of the
four BMI groups. Obese patients were more likely to have
hypertension and diabetes, but less likely to be smokers.
Patients in the overweight and obese categories had signif-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BMI 5 body mass index
BP 5 blood pressure
LV 5 left ventricle, left ventricular
HF 5 heart failure
LVEDD 5 left ventricular end-diastolic dimension
LVEF 5 left ventricular ejection fraction
PA 5 pulmonary artery
PCWP 5 pulmonary capillary wedge pressure
PIBW 5 percent ideal body weight
TNF-alpha 5 tumor necrosis factor-alpha
V˙O2 5 oxygen consumption
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icantly larger LVEDDs, yet significantly lower LVEDD
indexes. Peak oxygen consumption (V˙O2) was higher in
overweight and obese subjects, yet lower when corrected for
weight. Analysis of final hemodynamic variables after PA
catheter-guided medical therapy revealed higher cardiac
output, blood pressure (BP) and right atrial pressure in
patients with a higher BMI, but no significant difference in
final PA pressure, pulmonary capillary wedge pressure
(PCWP) or cardiac index. Serum sodium and creatinine
levels were similar in the four groups, but cholesterol,
triglycerides and low density lipoprotein cholesterol levels
were significantly higher and high density lipoprotein cho-
lesterol was significantly lower in the obese and overweight
patients. When patients were classified by PIBW, a similar
distribution of characteristics was seen, with the exception
of LVEF, which was significantly higher in the highest
PIBW group (23.0 6 7.0 in patients with PIBW .140% vs.
20.8 6 6.8 in patients with PIBW 80% to 100%), although
this difference did not reach significance (p 5 0.072) when
patients were stratified by BMI.
During the five years of follow-up (2,111 patient-years),
537 deaths occurred, with 350 occurring in the first year and
438 in the second year. Of the 537 total deaths, 143 deaths
were sudden, 174 were progressive HF deaths, 6 were
myocardial infarctions and 42 were from unknown or other
causes. During the follow-up, 172 patients received urgent
transplants. Figure 1 shows actuarial survival curves for the
four BMI categories. To assess the effect of obesity in
particular subsets of patients with HF, we recalculated
survival curves in clinically significant subgroups. Survival
curves for BMI categories were similar (p . 0.10) in
subgroups of men, women, patients with and without
Table 1. Baseline Characteristics Distributed Among the Four Categories of BMI
Underweight
(BMI <20.7)
Recommended
Weight
(BMI 20.7–27.7)
Overweight
(BMI 27.8–31)
Obese
(BMI >31) p Value*
n (%) 164 (13.6%) 692 (57.5%) 168 (14.0%) 131 (14.9%) —
Male (%) 64.6 79.2 81.5 73.2 0.000
Age (yrs) 48.4 6 15.4 53.2 6 11.4 52.5 6 10.0 48.5 6 11.5 0.000
Ejection fraction (%) 21.3 6 6.8 22.1 6 7 22.6 6 6.8 23.1 6 6.9 0.076
Peak V˙O2 (ml/min) 868 6 373 1,022 6 398 1,157 6 406 1,302 6 502 0.000
Peak V˙O2 (ml/kg per min) 15.0 6 0.6 13.9 6 0.3 12.9 6 0.4 12.6 6 0.4 0.002
Coronary artery disease (%) 42.7 51.2 49.4 39.1 0.015
Sudden death (%) 11.6 11.8 13.7 11.2 0.894
Severe MR (%) 36.5 33.1 27.6 22.3 0.016
Severe TR (%) 27.0 19.6 17.9 9.8 0.001
LVEDD (mm) 68 6 10 73 6 11 74 6 10 73 6 11 0.000
LVEDDI (LVEDD/BSA) (mm/m2) 42 6 7 39 6 6 37 6 6 34 6 6 0.000
Hypertension (%) 28.9 42.8 47.4 59.9 0.000
Diabetes (%) 10.9 24.0 37.1 43.2 0.000
Smokers (past and present) (%) 65.1 75.0 80.7 69.3 0.016
Serum sodium (mmol/l) 135 6 0.4 136 6 0.2 136 6 0.4 136 6 0.1 0.275
Serum creatinine (mg/dl) 1.3 6 0.7 1.4 6 0.9 1.4 6 1.2 1.7 6 2 0.140
Total cholesterol (mg/dl) 162 6 52 179 6 54 182 6 64 189 6 61 0.000
Triglycerides (mg/dl) 99 6 60 140 6 124 172 6 171 196 6 196 0.000
HDL cholesterol (mg/dl) 37 6 16 34 6 15 31 6 10 32 6 13 0.006
LDL cholesterol (mg/dl) 102 6 41 118 6 42 119 6 48 117 6 46 0.002
Heart transplants (%) 40.2 39.9 29.8 21.8 0.000
*p values reflect the Pearson chi-square test results for categorical variables and analysis of variance for continuous variables. Continuous variables are presented as the mean 6
SD, and categorical variables are presented as the percentage of patients.
BMI 5 body mass index; BSA 5 body surface area; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; LVEDD 5 left ventricular end-diastolic dimension;
LVEDDI 5 left ventricular end-diastolic dimension index; MR 5 mitral regurgitation; TR 5 tricuspid regurgitation; V˙O2 5 oxygen consumption.
Table 2. Final Hemodynamic Data on the Four BMI Categories After the Pulmonary Artery Catheter-Guided Unloading Protocol
Underweight
(BMI <20.7)
Recommended
Weight
(BMI 20.7–27.7)
Overweight
(BMI 27.8–31)
Obese
(BMI >31) p Value*
Systolic BP (mm Hg) 97 6 14 100 6 16 103 6 18 107 6 17 0.000
Diastolic BP (mm Hg) 56 6 11 58 6 12 60 6 10 63 6 12 0.000
Heart rate (beats/min) 90 6 18 86 6 16 88 6 16 90 6 15 0.010
Right atrial pressure (mm Hg) 7 6 4 7 6 4 7 6 4 9 6 8 0.000
MPAP (mm Hg) 25 6 8 26 6 8 25 6 8 26 6 7 0.883
PCWP (mm Hg) 15 6 6 15 6 6 15 6 6 16 6 6 0.420
Cardiac output (liters/min) 4.3 6 1.0 4.7 6 1.0 5.1 6 1.2 5.2 6 1.2 0.000
Cardiac index (liters/min per m2) 2.6 6 0.6 2.5 6 0.6 2.5 6 0.6 2.5 6 0.6 0.335
*p values reflect the Pearson chi-square test results. Data are presented as the mean value 6 SD.
BMI 5 body mass index; BP 5 blood pressure MPAP 5 mean pulmonary artery pressure; PCWP 5 pulmonary capillary wedge pressure.
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coronary artery disease, and patients dying suddenly. When
patients with transplants were eliminated from the analysis,
survival rates of the four BMI groups were still statistically
similar. There were no significant differences in the types of
death among the four BMI categories (p . 0.10).
On univariate analysis, LVEF, peak V˙O2, PCWP and
angiotensin-converting enzyme (ACE) inhibitor use were
predictors of mortality, whereas BMI and PIBW were not.
Table 4 shows the association between patient characteris-
tics and one-year survival. Table 5 shows the results of
multivariate analysis adjusting for age, gender, hypertension,
diabetes, LVEF, hemodynamic variables, peak V˙O2, mitral
regurgitation, tricuspid regurgitation, medicine use and
serum sodium, creatinine and lipid levels. Multivariate
analysis confirms that obesity did not increase mortality and
demonstrates that obesity was associated with a statistically
significant survival benefit at one and two years, but not at
five years of follow-up. The association between elevated
BMI and a reduced risk of death was not solely a function
of impaired survival in underweight, cachectic patients with
HF. Elevated BMI remained an independent predictor of
improved survival, even after the underweight patients were
eliminated from the analysis. Figure 2 shows five-year
survival curves by BMI adjusted for baseline differences.
DISCUSSION
Our initial hypothesis was that obese patients with HF
would have impaired survival, compared with patients of
recommended weight. Obesity is associated with an altered
hemodynamic profile and cardiovascular disease risk factors
that could be expected to increase both the risk of develop-
ing HF and the risk of mortality in patients with established
HF (6–8). In community cohort and insurance life-table
analyses, overweight status and obesity are risk factors for
cardiovascular and overall mortality at long-term follow-up
(16). Yet, we observed that obesity was not a significant risk
factor for five-year mortality in patients with advanced HF
and that excess body weight may, in fact, confer survival
benefit to patients with HF.
Despite the wide prevalence of both HF and obesity, few
previous studies have addressed the role of obesity in HF
survival. A study of prognostic variables in 401 patients with
HF did not find overweight status to be a risk factor for
mortality, despite inclusion of .40% overweight patients
(BMI .26) (17). Similar findings were also seen in a recent
preliminary report involving a retrospective analysis of 589
patients with HF. This study reported that survival was not
impaired in obese patients with HF and that mildly obese
patients had the most favorable prognosis (18). A similar
relationship has been observed between obesity, essential
hypertension and mortality. Overweight status was associ-
ated with decreased stroke risk and decreased total mortal-
ity, compared with lean subjects in the Systolic Hyperten-
sion in the Elderly Program study (19).
Hemodynamic alterations in obesity. Several explana-
tions for obesity’s potentially protective role in HF merit
discussion and further investigation. Despite similar
PCWPs and cardiac indexes, overweight and obese patients
had higher BPs. Improved BP tolerance to afterload-
reducing agents may explain why a larger proportion of
obese and overweight patients were on ACE inhibitors,
which are known to prolong the lives of patients with
advanced HF (20).
Figure 1. Actuarial survival curves for the four body mass index (BMI)
categories at five years. Survival, free of urgent heart transplantation or
death, was not statistically different for any of the four BMI categories (p 5
0.9383).
Table 3. Medicine Use Among the Four Categories of BMI
Underweight
(BMI <20.7)
Recommended
Weight
(BMI 20.7–27.7)
Overweight
(BMI 27.8–31)
Obese
(BMI >31.1) p Value*
Antiarrhythmics agents, all types 37.8 45.1 42.9 38 0.184
Amiodarone 28.7 33.6 31.7 28.5 0.457
Type 1 9.1 11.6 11.3 9.5 0.748
ACE inhibitors 63.4 70.4 77.4 73.7 0.034
Nitrates 59.1 67.9 74.3 69.8 0.027
Digoxin 64.6 67.9 70.5 67 0.911
Coumadin 38.4 36.1 47.9 37.4 0.047
Statins 2.7 8.8 10.3 7.7 0.133
*p values reflect the Pearson chi-square test results. Data are presented as the percentage of patients.
ACE 5 angiotensin-converting enzyme inhibitors; BMI 5 body mass index.
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Lipoproteins. The interaction between obesity and serum
lipid levels is also a potential explanation for the survival
advantage seen in obese patients. Our data show a signifi-
cant positive correlation between higher cholesterol levels
and improved survival, and this trend has been noted in
previous studies (21). Other investigators have postulated
that serum lipoproteins play a beneficial role in HF through
downregulation of inflammatory cytokines (22).
Neurohormonal alterations in obesity. Altered cytokine
and neuroendocrine profiles of obese patients may play a
role in modulating HF progression. Changes in the cytokine
tumor necrosis factor-alpha (TNF-alpha) system are ob-
served in obese patients. Adipose tissue produces soluble
TNF-alpha receptors, resulting in higher circulating levels
of both type I and II receptors in obese subjects (23).
Soluble TNF-alpha receptors are also elevated in HF and
may play a cardioprotective role, as they neutralize the
biologic effects of TNF-alpha. Tumor necrosis factor-alpha
is elevated in HF and may contribute to cardiac injury
through its pro-apoptotic and negative inotropic effects
(24).
Obesity has also been associated with alterations in the
sympathetic nervous system and renin-angiotensin system.
A recent study comparing exercise responses in obese and
lean subjects found that the lean ones had significantly
higher increases in plasma epinephrine and renin levels
Figure 2. Risk-adjusted survival curves for the four body mass index (BMI)
categories at five years. The variables entered into the equation were age,
gender, hypertension, diabetes mellitus, left ventricular ejection fraction,
hemodynamic variables, peak V˙O2), mitral regurgitation, tricuspid regur-
gitation, medications and serum sodium, creatinine and lipid levels.
Survival was significantly better for the overweight and obese BMI
categories.
Table 4. Prediction of One-Year Survival by Univariate Analysis
Survivors Nonsurvivors p Value*
Relative Risk
(95% Confidence Interval)
Body mass index 25.8 6 5.6 25.6 6 5.2 0.496 —
Percent ideal body weight 118.6 6 31.8 117.4 6 24.3 0.511 —
Age (years) 51.8 6 11.6 51.6 6 12.9 0.991 —
Hypertension (%) 44.9 43.0 0.537 —
Diabetes (%) 26.9 28.3 0.791 —
History of smoking (%) 73.3 74.6 0.758 —
Significant predictors
Ejection fraction (%) 23 6 7 21 6 7 0.006 0.978 (0.963–0.994)
Coronary artery disease (%) 45.1 55.0 0.001 1.433 (1.161–1.768)
Peak V˙O2 (ml/kg per min) 14.0 6 4.9 12.1 6 4.5 0.0001 0.545 (0.490–0.605)
LVEDDI (mm/m2) 72 6 10 73 6 12 0.0001 1.034 (1.017–1.051)
PCWP (mm Hg) 14.4 6 5.2 17.6 6 6.3 0.0001 1.085 (1.067–1.104)
ACE inhibitor use (%) 77.4 56.1 0.0001 0.438 (0.354–0.541)
Total cholesterol (mg/dl) 184 6 54 164 6 58 0.0001 0.994 (0.992–0.996)
*p values reflect the likelihood ratio test by the Cox model. Continuous variables are presented as the mean value 6 SD, and
categorical variables are presented as the percentage of patients.
Abbreviations as in Tables 1, 2 and 3.
Table 5. Predictors of Survival by Multivariate Cox
Regression Analysis
p Value
Relative Risk
(95% Confidence Interval)
One year
BMI (higher) 0.072 0.960 (0.918–1.004)
PIBW* (higher) 0.117 —
Age (older) 0.072 0.983 (0.964–1.002)
MR (less) 0.024 1.463 (1.050–2.037)
PCWP (lower) 0.010 1.065 (1.016–1.117)
Serum sodium (higher) 0.029 0.937 (0.883–0.993)
Peak V˙O2 (higher) 0.000 0.548 (0.436–0.690)
Two years
BMI (higher) 0.016 0.952 (0.915–0.991)
PIBW* (higher) 0.005 0.986 (0.977–0.995)
Age (older) 0.006 0.976 (0.960–0.993)
PCWP (lower) 0.057 1.043 (0.999–1.089)
Serum sodium (higher) 0.014 0.938 (0.892–0.987)
Peak V˙O2 (higher) 0.000 0.654 (0.540–0.792)
ACE inhibitor (presence) 0.066 0.630 (0.385–1.031)
Five years
BMI (higher) 0.259 —
PIBW* (higher) 0.299 —
Age (older) 0.076 0.986 (0.970–1.001)
MR (less) 0.008 1.3888 (1.088–1.771)
Total cholesterol (higher) 0.018 0.995 (0.991–0.999)
Peak V˙O2 (higher) 0.000 0.619 (0.529–0.724)
ACE inhibitor (presence) 0.026 0.612 (0.397–0.942)
*Percent ideal body weight (PIBW) was entered into a separate Cox model, in place
of BMI.
Abbreviations as in Tables 1, 2 and 3.
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during treadmill testing, despite similar baseline levels and
history of hypertension (25). Because heightened sympa-
thetic and renin-angiotensin activity are associated with a
poor HF prognosis (26), diminished stress responses of
these neurohormonal systems may provide insight into the
favorable HF prognosis seen in obesity.
It could be rationalized that obese patients present at an
earlier, less severe stage of disease as a consequence of more
prominent symptoms of dyspnea and greater functional
impairment associated with excess body weight. However,
LVEF and other measures of the severity of illness were not
different in obese patients, and after adjustment in multi-
variate analysis, obesity was not associated with a worse
prognosis. In addition, patients with a higher BMI were less
likely to receive heart transplants. Because a similar percent-
age of obese patients and those of recommended weight
were accepted for transplantation, the lower rate of trans-
plants in obese patients was likely secondary to reduced
availability of larger-sized hearts for transplant. In this
study, 21.8% of obese patients received heart transplants,
compared with 39.9% of those of recommended weight.
This disparity would be expected to adversely effect observed
survival in the obese group of patients with advanced HF.
Even if obesity is not associated with worse HF survival,
weight loss may be desirable if it results in improved
functional capacity and reduced symptoms. Furthermore,
preoperative obesity may increase morbidity and mortality
with heart transplantation (14). However, if obesity is
protective, then weight loss attempts could be associated
with increased mortality risk. Further studies are needed to
examine the risks and benefits of weight loss in patients with
HF.
Although our observations do not directly address the
role of obesity in the development of HF, the distribution of
obesity in our study is similar to that reported for the U.S.
adult population (4). Selection bias in referral to a transplant
center may account for the relatively normal weight distri-
bution seen in this cohort of patients with advanced HF.
Our study has several strengths. Its large sample size
provides adequate power to detect true differences in sur-
vival. The study involves a single center, allowing for
accurate and thorough follow-up data. We have eliminated
the potential confounding variable of edematous weight
gain in our calculation of BMI by using weights recorded
after therapy, aimed at hemodynamic optimization and
euvolemia. Our data base includes numerous demographic,
laboratory, echocardiographic and hemodynamic variables,
permitting a detailed and adequately powered survival anal-
ysis.
The potential limitations of our study include its retro-
spective nature and our selected group of patients with
advanced HF disease referred for transplant evaluation. The
study took place over a period when HF treatments were
changing, although the rates of obesity were evenly distrib-
uted over the study period. Data on the use of beta-blockers
and doses of ACE inhibitors are not available. We also do
not have data on cytokine or neurohormonal levels, or direct
measures of percent body fat. Furthermore, we have not
accounted for the body distribution of adipose tissue, which
may confer differential risks of cardiovascular disease. An
additional limitation is that BMI was assessed at a single
point in time. Cachexia has been associated with an unfa-
vorable prognosis when defined by weight loss rather than
absolute weight, and change in weight over time was not
evaluated in our study (27).
Conclusions. In this cohort of patients with advanced HF
followed in a comprehensive HF center, elevated BMI was
not associated with increased mortality. Furthermore, ele-
vated BMI was an independent predictor of improved
survival at one and two years. The present findings suggest
that promotion of weight loss in patients with HF may not
lower the mortality risk, and may even be potentially
harmful. Further investigations into the interaction between
obesity and progression of HF are needed.
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